recurrent angina

recurrent angina

Cardiology Sharp precordial pain directly related to cardiac ischemia, seen in 3-5% of Pts with CABG, due either to progressive stenosis or occlusion of a CABG or progressive stenosis in an ungrafted artery. See Angina, CABG, Triple-bypass surgery.
References in periodicals archive ?
This risk was largely driven by an increased risk of heart attack and recurrent angina requiring further coronary stenting.
Patients with chronic obstructive pulmonary disease, orthopedic impediments, recent hospitalization (within 3 months), and myocardial infarction or recurrent angina (within 6 months) were excluded from the trial.
No recurrent angina was observed after the catheterization procedure, and the patient was discharged on the fourth day without any symptoms.
Generx is designed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions, such as recurrent angina, due to coronary artery disease.
The guidelines also call for treatment with a glycoprotein IIb/IIIa inhibitor, such as eptifibatide (Integrilin), tirofiban (Aggrastat), or abciximab (ReoPro) for recurrent angina or prior to diagnostic angiography or coronary stenting.
We are pleased that the FDA has recognized the urgent and unmet medical need for effective new therapies for the treatment of patients with recurrent angina associated with heart disease," stated Christopher J.
Studies show that, compared with surgery, stenting results in an almost threefold increase in recurrent angina and an almost fourfold increase in the need for re-intervention.
An additional follow-up study of Generx in men with recurrent angina due to myocardial ischemia is expected to commence later.
On the other hand, the long-term outlook after PCI can be affected by neo-intimal proliferation at the site of PCI, leading to in-stent restenosis, recurrent angina, and ultimately, target-lesion revascularization (3).
Previously, the ESSENCE trial had shown that administration of enoxaparin to patients with unstable angina and non-Q-wave MI reduced the incidence of death, myocardial infarction and recurrent angina by 3.
The ESSENCE study showed that enoxaparin was more effective than IV unfractionated heparin in reducing the incidence of death, myocardial infarction or recurrent angina in patients with unstable angina or NQWMI.